Cartesian Therapeutics (RNAC) FCF Margin (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly FCF Margin of 28412.82% for Q1 2026, down 2621437.0% year-over-year from N/an in Q1 2025, and down 1067.08% quarter-over-quarter from 2434.53% in Q4 2025.
Cartesian Therapeutics (RNAC) FCF Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported FCF Margin for 12 consecutive years, with 28412.82% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 2621437.0% year-over-year to 28412.82%; the TTM figure through Mar 2026 stood at 7548.68% (down 745091.0% YoY), while the FY2025 annual figure was 2838.58%, down 277451.0% from the prior year.
- FCF Margin retreated to 28412.82% in Q1 2026 per RNAC's latest filing, from 2434.53% in the prior quarter.
- Across five years, FCF Margin topped out at 891.99% in Q4 2024 and bottomed at 28412.82% in Q1 2026.
- Historically, FCF Margin has averaged 2382.75% across 5 years, with a median of 145.36% in 2023.
- Annual changes were most pronounced in 2024 — FCF Margin jumped 117446 bps — and 2026, when it tumbled 2621437 bps.
- Cartesian Therapeutics' FCF Margin stood at 76.84% in 2022, then plunged by 268 bps to 282.47% in 2023, then jumped by 416 bps to 891.99% in 2024, then tumbled by 373 bps to 2434.53% in 2025, then sank by 1067 bps to 28412.82% in 2026.
- Business Quant data shows RNAC's FCF Margin at 28412.82% in Q1 2026, 2434.53% in Q4 2025, and 2198.45% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28,412.82% |
| Dec 31, 2025 | -2,434.53% |
| Mar 31, 2025 | -2,198.45% |
| Dec 31, 2024 | 891.99% |
| Jun 30, 2024 | -50.00% |
| Mar 31, 2024 | -272.55% |
| Dec 31, 2023 | -282.47% |
| Sep 30, 2023 | -140.93% |
| Jun 30, 2023 | -186.95% |
| Mar 31, 2023 | -149.80% |
| Dec 31, 2022 | -76.84% |
| Sep 30, 2022 | 21.86% |
| Jun 30, 2022 | -31.83% |
| Mar 31, 2022 | -35.16% |
| Dec 31, 2021 | -108.65% |
| Sep 30, 2021 | -41.43% |
| Jun 30, 2021 | -33.88% |
| Mar 31, 2021 | -110.03% |
| Dec 31, 2020 | -55.47% |
| Sep 30, 2020 | 1,406.50% |